#BEGIN_DRUGCARD DB00709

# AHFS_Codes:
08:18.08.20

# ATC_Codes:
J05AF05

# Absorption:
Lamivudine was rapidly absorbed after oral administration in HIV-infected patients. Absolute bioavailability in adults is 86% &plusmn; 16% for the tablet and 87% &plusmn; 13% for the oral solution.

# Biotransformation:
The only detected metabolite of lamivudine is trans-sulfoxide.

# Brand_Mixtures:
Combivir (Lamivudine + Zidovudine)
Epzicom (Abacavir Sulfate + Lamivudine)
Kivexa (Abacavir Sulfate + Lamivudine)
Trizivir (Abacavir Sulfate + Lamivudine + Zidovudine)

# Brand_Names:
3TC
Epivir
Epivir-HBV
Hepitec
Heptovir
Zeffix

# CAS_Registry_Number:
134678-17-4

# ChEBI_ID:
Not Available

# Chemical_Formula:
C8H11N3O3S

# Chemical_IUPAC_Name:
4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-1,2-dihydropyrimidin-2-one

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
2239194

# Description:
A reverse transcriptase inhibitor and zalcitabine analog in which a sulfur atom replaces the 3&#39; carbon of the pentose ring. It is used to treat Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV).

# Dosage_Forms:
Solution	Oral
Tablet	Oral

# Drug_Category:
Anti-HIV Agents
Nucleoside and Nucleotide Reverse Transcriptase Inhibitors
Reverse Transcriptase Inhibitors

# Drug_Interactions:
Tobramycin	Increased risk of nephrotoxicity
Valganciclovir	The adverse/toxic effects of reverse transcriptase inhibitors (nucleoside), such as Lamivudine, may be enhanced by Valganciclovir. There is a risk of hematologic toxicity. Diligent monitoring during concomitant therapy is recommended.
Zalcitabine	Lamivudine may reduce the efficacy of zalcitabine. Combination therapy is not recommended.

# Drug_Reference:
17310820	Fox Z, Dragsted UB, Gerstoft J, Phillips AN, Kjaer J, Mathiesen L, Youle M, Katlama C, Hill A, Bruun JN, Clumeck N, Dellamonica P, Lundgren JD: A randomized trial to evaluate continuation versus discontinuation of lamivudine in individuals failing a lamivudine-containing regimen: the COLATE trial. Antivir Ther. 2006;11(6):761-70.

# Drug_Type:
Approved
Investigational
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
-1.4

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
70 mg/ml

# Food_Interactions:
Take without regard to meals. Food does not decrease the extent of absorption, but it decreases the Cmax by slowing the rate of absorption.

# GenBank_ID:
Not Available

# Generic_Name:
Lamivudine

# HET_ID:
Not Available

# Half_Life:
5 to 7 hours

# InChI_Identifier:
InChI=1S/C8H11N3O3S/c9-5-1-2-11(8(13)10-5)6-4-15-7(3-12)14-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7+/m0/s1

# InChI_Key:
InChIKey=JTEGQNOMFQHVDC-NKWVEPMBSA-N

# Indication:
For the treatment of HIV infection and chronic hepatitis B (HBV).

# KEGG_Compound_ID:
C07065

# KEGG_Drug_ID:
D00353

# LIMS_Drug_ID:
709

# Mechanism_Of_Action:
Lamivudine is a synthetic nucleoside analogue and is phosphorylated intracellularly to its active 5'-triphosphate metabolite, lamivudine triphosphate (L-TP). This nucleoside analogue is incorporated into viral DNA by HIV reverse transcriptase and HBV polymerase, resulting in DNA chain termination.

# Melting_Point:
160-162 Â°C

# Molecular_Weight_Avg:
229.256

# Molecular_Weight_Mono:
229.052111923

# Organisms_Affected:
Hepatitis B virus
Human Immunodeficiency Virus

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/com1513.shtml

# Pathways:
Not Available

# PharmGKB_ID:
PA450163

# Pharmacology:
Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV). Lamivudine is phosphorylated to active metabolites that compete for incorporation into viral DNA. They inhibit the HIV reverse transcriptase enzyme competitively and act as a chain terminator of DNA synthesis. The lack of a 3'-OH group in the incorporated nucleoside analogue prevents the formation of the 5' to 3' phosphodiester linkage essential for DNA chain elongation, and therefore, the viral DNA growth is terminated.

# Predicted_LogP_Hydrophobicity:
-1.3

# Predicted_LogS:
-1.9

# Predicted_Water_Solubility:
2.76e+00 g/l

# Primary_Accession_No:
DB00709

# Protein_Binding:
36%

# PubChem_Compound_ID:
60825

# PubChem_Substance_ID:
46507855

# RxList_Link:
http://www.rxlist.com/cgi/generic3/lamivudine.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00681

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Lamivudine [Usan:Ban:Inn]

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:19:34 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Lamivudine

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
Not Available

# Drug_Target_1_GenBank_ID_Protein:
Not Available

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
Not Available

# Drug_Target_1_Gene_Sequence:
Not Available

# Drug_Target_1_General_Function:
Not Available

# Drug_Target_1_General_References:
Not Available

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
7243

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
Not Available

# Drug_Target_1_Name:
Reverse transcriptase

# Drug_Target_1_Number_of_Residues:
0

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
Not Available

# Drug_Target_1_Protein_Sequence:
Not Available

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
Not Available

# Drug_Target_1_Specific_Function:
Not Available

# Drug_Target_1_SwissProt_ID:
Q5DNL9

# Drug_Target_1_SwissProt_Name:
Not Available

# Drug_Target_1_Synonyms:
Not Available

# Drug_Target_1_Theoretical_pI:
Not Available

# Drug_Target_1_Transmembrane_Regions:
Not Available

# Drug_Target_2_Cellular_Location:
Nucleus and mitochondria

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
17900250	Dai CY, Yu ML, Hsieh MY, Lee LP, Hou NJ, Huang JF, Chen SC, Lin ZY, Hsieh MY, Wang LY, Tsai JF, Chang WY, Chuang WL: Early response to lamivudine therapy in clinically non-cirrhotic chronic hepatitis B patients with decompensation. Liver Int. 2007 Sep 27;.
17922993	Ma H, Guo F, Wei L, Sun Y, Wang H: [The prospective study of the clinical features and outcome of HBeAg-negative and HBeAg-positive cirrhosis in patients with chronic type B hepatitis] Zhonghua Yi Xue Za Zhi. 2007 Jul 10;87(26):1832-5.
17927612	Pan XP, Li LJ, Du WB, Li MW, Cao HC, Sheng JF: Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C. J Viral Hepat. 2007 Nov;14(11):767-74.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
Not Available

# Drug_Target_2_GenBank_ID_Protein:
Not Available

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
Not Available

# Drug_Target_2_Gene_Sequence:
>Example: Dickerson dodecamer
CGCGAATTCGCG

# Drug_Target_2_General_Function:
Biological information storage and information transfer

# Drug_Target_2_General_References:
1234	Nadeau D, Marchand C: Change in the kinetics of sulphacetamide tissue distribution in Walker tumor-bearing rats. Drug Metab Dispos. 1975 Nov-Dec;3(6):565-76.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
874

# Drug_Target_2_Locus:
All loci

# Drug_Target_2_Molecular_Weight:
7656 (double strand)

# Drug_Target_2_Name:
DNA

# Drug_Target_2_Number_of_Residues:
0

# Drug_Target_2_PDB_ID:
1BNA

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
Not Available

# Drug_Target_2_Protein_Sequence:
Not Available

# Drug_Target_2_Reaction:
DNA + DNA polymerase + nNTP = 2 DNA + nNDP; DNA + RNA polymerase + NTP = mRNA + nNDP

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
DNA is the molecule of heredity, as it is responsible for the genetic propagation of most inherited traits. It is a polynucleic acid that carries genetic information on cell growth, division, and function. DNA consists of two long strands of nucleotides twisted into a double helix and held together by hydrogen bonds. The sequence of nucleotides determines hereditary characteristics. Each strand serves as the template for subsequent DNA replication and as a template for mRNA production, leading to protein synthesis via ribosomes.

# Drug_Target_2_SwissProt_ID:
Not Available

# Drug_Target_2_SwissProt_Name:
Not Available

# Drug_Target_2_Synonyms:
Deoxyribonucleic acid

# Drug_Target_2_Theoretical_pI:
Not Available

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Cytoplasmic

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
11230757	Stuyver LJ, Locarnini SA, Lok A, Richman DD, Carman WF, Dienstag JL, Schinazi RF: Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology. 2001 Mar;33(3):751-7.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
Not Available

# Drug_Target_3_GenBank_ID_Gene:
X69798

# Drug_Target_3_GenBank_ID_Protein:
59427

# Drug_Target_3_GeneCard_ID:
Not Available

# Drug_Target_3_Gene_Name:
P

# Drug_Target_3_Gene_Sequence:
>2532 bp
ATGCCCCTATCCTATCCACACTTCCGGAAACTACTGTTGTTAGACGACGAGGCAGGTCCC
CTAGAAGAAGAACTCCCTCGCCTCGCAGACGAAGATCTCAATCGCCGCGTCGCCGCAGAT
CTCAATCTCCAGCTTCCCAATGTTAGTATTCCTTGGACTCATAAGGTGGGAAACTTTACG
GGGCTTTACTCTTCTACTGTGCCTGCTTTTAATCCTAACTGGTCCACTCCTTCTTTTCCT
GATATTCATTTGCATCAAGACCTGATTTCTAAATGTGAACAATTTGTAGGCCCACTTACT
AAAAATGAATTACGAAGATTAAAATTGGTTATGCCAGCTAGATTTTATCCTAAGGTTACC
AAATATTTTCCCATGGATAAAGGCATCAAACCCTATTATCCTGAGCATGCAGTTAATCAT
TACTTTAAAACCAGACATTATTTGCATACTTTATGGAAGGCGGGAATTTTATATAAGAGA
GAATCCACACGTAGCGCCTCATTTTGTGGGTCACCATATTCCTGGGAACAAGAGCTACAG
CATGGGAGCACCTCTCTCAACGACACGAAGAGGCATGGGACAGAATCTCTCTGTGCCCAA
TCCTCTGGGATTCTTTCCAGACCATCAGCTGGATCCGCTATTCAGAGCAAATTCCAGCAG
TCCCGACTGGGACTTCAACACAAACAAGGACAGTTGGCCAATGGCAAACAAGGTAGGAGT
GGGAGGCTACGGTCCAGGGTTCACACCCCCACACGGTGGCCTGCTGGGGTGGAGCCCTCA
AGCACAAGGTGTGTTAACAACCTTGCCAGCAGATCCGCCTCCTGCTTCCACCAATCGGCG
GTCCGGGAGAAAGCCAACCCCAGTCTCTCCACCTCTAAGAGACACACATCCACAGGCAAT
GCAGTGGAACTCAACCCAGTTCCACCAAGCTCTGTTGGATCCCAGGGTAAGGGCTCTGTA
CTTCCCTGCTGGTGGCTCCAGTTCAGGGACACAGAACCCTGCTCCGACTATTGCCTCTCT
CACATCATCAATCTTCTCGAAGACTGGGGGCCCTGCTATGAACATGGACAACATTACATC
AGGACTCCTAGGACCCCTGCTCGTGTTACAGGCGGTGTGTTTCTTGTTGACAAAAATCCT
CACAATACCACAGAGTCTAGACTCGTGGTGGACTTCTCTCAATTTTCTAGGGGGACTACC
CGGGTGTCCTGGCCAAAATTCGCAGTCCCCAACCTCCAATCACTTACCAACCTCCTGTCC
TCCAACTTGTCCTGGCTATCGTTGGATGTGTCTGCGGCGTTTTATCATCTTCCTCTTCAT
CCTGCTGCTATGCCTCATCTTCTTGTTGGTTCTTCTGGACTATCAAGGTATGTTGCCCGT
TTGTCCTCTACTTCCAGGATCCACGACCACCAGCACGGGACCCTGCAAAACCTGCACAAC
TCTTGCACAAGGAACCTCTATGTTTCCCTCCTGTTGCTGTTCCAAACCCTCGGACGGAAA
CTGCACTTGTATTCCCATCCCATCATCCTGGGCTTTAGGAAAATACCTATGGGAGTGGGC
CTCAGCCCGTTTCTCCTGGCTCAGTTTACTAGTGCAATTTGTTCAGTGGTGCGTCGGGCT
TTCCCCCACTGTTTGGCTTTTAGTTATATGGATGATCTGGTATTGGGGGCCAAATCTGTG
CAGCATCTTGAGTCCCTTTATACCGCTGTTACCAATTTTCTGTTATCTGTGGGTATCCAT
TTAAATACCTCTAAAACAAAAAGATGGGGTTACTCCCTACATTTTATGGGTTATGTCATT
GGTAGTTGGGGATCATTACCCCAAGATCACATTGTACACAAAATCAAGGAATGCTTTCGA
AAACTGCCTGTAAATCGTCCAATTGATTGGAAAGTTTGTCAACGCATAGTGGGTCTTTTG
GGCTTTGCTGCCCCTTTCACCCAATGCGGTTATCCTGCTCTCATGCCTCTGTATGCCTGT
ATTACTGCTAAACAGGCTTTTGTCTTCTCGCCAACCTACAAGGCCTTTCTGTGTAAACAA
TACATGAACCTTTACCCGGTTGCTCGGCAACGGCCAGGCCTGTGCCAAGTGTTTGCTGAC
GCAACCCCCACTGGTTGGGGCTTGGCCATTGGCCATCAGCGCATGCGTGGAACCTTTGTG
GCTCCTCTGCCGATCCATACTGCGGAACTCCTAGCAGCTTGTTTCGCTCGCAGCAGGTCT
GGAGCGACTCTCATCGGCACGGACAATTCTGTTGTCCTCTCTAGGAAGTACACCTCCTTT
CCATGGCTGCTCGGATGTGCTGCAAACTGGATCCTGCGCGGGACGTCCTTTGTTTACGTC
CCATCGGCGCTGAATCCCGCGGACGACCCCTCCCGGGGCCGCTTGGGGCTGTACCGCCCT
CTTCTCCGTCTGCCGTTCCAGCCGACGACGGGTCGCACCTCTCTTTACGCGGACTCCCCG
TCTGTTCCTTCTCATCTGCCGGACCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGG
AGACCACCGTGA

# Drug_Target_3_General_Function:
Involved in RNA binding

# Drug_Target_3_General_References:
8345355	Naumann H, Schaefer S, Yoshida CF, Gaspar AM, Repp R, Gerlich WH: Identification of a new hepatitis B virus (HBV) genotype from Brazil that expresses HBV surface antigen subtype adw4. J Gen Virol. 1993 Aug;74 ( Pt 8):1627-32.

# Drug_Target_3_HGNC_ID:
Not Available

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
612

# Drug_Target_3_Locus:
Not Available

# Drug_Target_3_Molecular_Weight:
94259

# Drug_Target_3_Name:
P protein [Includes: DNA-directed DNA polymerase

# Drug_Target_3_Number_of_Residues:
843

# Drug_Target_3_PDB_ID:
Not Available

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00078	RVT_1
PF00242	DNA_pol_viral_N
PF00336	DNA_pol_viral_C

# Drug_Target_3_Protein_Sequence:
>P protein [Includes: DNA-directed DNA polymerase
MPLSYPHFRKLLLLDDEAGPLEEELPRLADEDLNRRVAADLNLQLPNVSIPWTHKVGNFT
GLYSSTVPAFNPNWSTPSFPDIHLHQDLISKCEQFVGPLTKNELRRLKLVMPARFYPKVT
KYFPMDKGIKPYYPEHAVNHYFKTRHYLHTLWKAGILYKRESTRSASFCGSPYSWEQELQ
HGSTSLNDTKRHGTESLCAQSSGILSRPSAGSAIQSKFQQSRLGLQHKQGQLANGKQGRS
GRLRSRVHTPTRWPAGVEPSSTRCVNNLASRSASCFHQSAVREKANPSLSTSKRHTSTGN
AVELNPVPPSSVGSQGKGSVLPCWWLQFRDTEPCSDYCLSHIINLLEDWGPCYEHGQHYI
RTPRTPARVTGGVFLVDKNPHNTTESRLVVDFSQFSRGTTRVSWPKFAVPNLQSLTNLLS
SNLSWLSLDVSAAFYHLPLHPAAMPHLLVGSSGLSRYVARLSSTSRIHDHQHGTLQNLHN
SCTRNLYVSLLLLFQTLGRKLHLYSHPIILGFRKIPMGVGLSPFLLAQFTSAICSVVRRA
FPHCLAFSYMDDLVLGAKSVQHLESLYTAVTNFLLSVGIHLNTSKTKRWGYSLHFMGYVI
GSWGSLPQDHIVHKIKECFRKLPVNRPIDWKVCQRIVGLLGFAAPFTQCGYPALMPLYAC
ITAKQAFVFSPTYKAFLCKQYMNLYPVARQRPGLCQVFADATPTGWGLAIGHQRMRGTFV
APLPIHTAELLAACFARSRSGATLIGTDNSVVLSRKYTSFPWLLGCAANWILRGTSFVYV
PSALNPADDPSRGRLGLYRPLLRLPFQPTTGRTSLYADSPSVPSHLPDRVHFASPLHVAW
RPP

# Drug_Target_3_Reaction:
deoxynucleoside triphosphate + DNAn = diphosphate + DNAn+1

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
Not Available

# Drug_Target_3_SwissProt_ID:
Q05486

# Drug_Target_3_SwissProt_Name:
DPOL_HBVF1

# Drug_Target_3_Synonyms:
EC 3.1.26.4]
RNA- directed DNA polymerase
Ribonuclease H

# Drug_Target_3_Theoretical_pI:
10.12

# Drug_Target_3_Transmembrane_Regions:
None

#END_DRUGCARD DB00709
